FOXP3 and neoplasm: Dividing the cases by tumor subtype, the FOXP3+ survival improvement was observed in UUS, and as a nonsignificant trend in ESS (p = 0.0269 and p = 0.0954, respectively), but not in LMS (Supplementary Fig. 3).